Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.747011
Title: Genomic classification and analysis of epilepsy-associated glioneuronal tumours
Author: Stone, Thomas John
ISNI:       0000 0004 7227 8909
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
INTRODUCTION: Glioneuronal tumours are a group of low-grade epilepsy-associated tumours with marked variability in their histological features, resulting in a lack of diagnostic consensus between institutions. This is confounded by a dearth of knowledge regarding their underlying biology, and subsequent lack of robust biologically informed diagnostic tools. This lack of understanding also impedes the development of novel and targeted treatment strategies. METHODS: I have undertaken a comprehensive molecular analysis of the most prevalent glioneuronal tumours: ganglioglioma and dysembryoplastic neuroepithelial tumours. I have used RNA sequencing and Illumina 450K methylation arrays to classify tumours in an unsupervised manner according to their genomic profiles. I then carried out in silico analyses on these datasets to identify genes, gene networks, and pathways that are differentially regulated between groups. Additionally, I have undertaken molecular assays to identify mutations that are specific to each group. Finally, I have used immunohistochemistry to assess a number of potential diagnostic markers revealed by expression profiling. RESULTS: Unsupervised clustering revealed glioneuronal tumours classify into two molecular groups (termed Group 1 and Group 2), which are only partially consistent with histological classification. Group 1 is defined by an astrocytic expression phenotype and an enrichment for BRAF-V600E mutations. Group 2 is defined by an oligodendrocyte precursor phenotype and an enrichment for FGFR1 mutations. A number of disease relevant networks and pathways are differentially regulated between these groups. Additionally, immunohistochemistry against Cyclin-D1 and PDGFRα can be used to distinguish tumour groups from one another. CONCLUSION: This is the first comprehensive genomic investigation of a large cohort of glioneuronal tumours without prior histological bias. I present data suggesting the current histological classification of these lesions is insufficient, and recommend a novel biologically informed strategy. My results also provide insight into the pathways underlying the development of these tumours. This information may assist in the development of novel treatment strategies.
Supervisor: Jacques, T. S. ; Ham, J. Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.747011  DOI: Not available
Share: